CN111529623A - Yin-nourishing and sore-throat-relieving pharmaceutical composition - Google Patents

Abstract

The invention belongs to the field of traditional Chinese medicines, and relates to a yin-nourishing and sore-throat-relieving pharmaceutical composition. Specifically, the invention relates to a yin-nourishing and sore-throat-relieving tea bag. The invention also relates to a quality control method and pharmaceutical application of the pharmaceutical composition. Specifically, the present invention relates to a pharmaceutical composition comprising: 6-10 parts of radix pseudostellariae, 6-10 parts of radix ophiopogonis, 8-12 parts of lotus leaves, 8-12 parts of folium isatidis, 2-4 parts of mint, 8-12 parts of burdock, 6-10 parts of rhizoma cimicifugae, 8-12 parts of fructus forsythiae, 6-10 parts of radix paeoniae rubra, 4-8 parts of liquorice and 8-12 parts of green tea. The pharmaceutical composition has the effects of tonifying qi, moistening lung, clearing throat, relieving sore throat, removing dirt, eliminating turbid pathogen and the like, and has the potential of being applied to preparation of medicines for treating and/or preventing pharyngitis.

Description

Yin-nourishing and sore-throat-relieving pharmaceutical composition

Technical Field

The invention belongs to the field of traditional Chinese medicines, and relates to a yin-nourishing and sore-throat-relieving pharmaceutical composition. Specifically, the invention relates to a yin-nourishing and sore-throat-relieving tea bag. The invention also relates to a quality control method and pharmaceutical application of the pharmaceutical composition.

Background

Pneumococci and hemolytic streptococcus often cause adverse inflammatory stimulation to pharyngeal mucosa and tonsil, so that acute and chronic pharyngitis, deficiency and pharyngitis are the symptoms of acute and chronic pharyngitis, dry cough, intractable and recurrent attacks^[1,2]. Heat-toxicity and wind-cold tend to lead to qi and blood stasis, which often induces throat diseases in qi and blood with imbalance of yin and yang, so acute and chronic pharyngitis, which is "yin-yang stagnation" in the "internal classic", and deficiency of yin of the throat, lung and kidney, often leads to stagnation of deficient fire. The traditional Chinese medicine is characterized by applying dialectical treatment of blood stasis and qi deficiency, such as a kidney warming and lung moistening method, a qi circulation and spleen tonifying method, a yin nourishing and sore throat relieving method, a kidney warming and yang strengthening method, a qi circulation and blood activating method and the like.

The traditional Chinese medicine acupoint application method, acupuncture therapy, moxibustion therapy, electric needle and acupoint injection method, etc. can be used for treating acute and chronic pharyngitis by synthesizing traditional Chinese medicine according to channels and collaterals, traditional Chinese medicine intravenous injection method, traditional Chinese medicine aerosol inhalation method, etc^[3-6]。

He hong, etc^[7]Respectively applying the experience of using the self-prepared Yinma decoction to treat 35 patients with chronic pharyngitis and applying the experience of using the self-prepared mulberry cicada cough relieving prescription to 45 patients with chronic pharyngitis. Usually for external treatmentTreatment measures including massage, acupuncture therapy and ultrasonic atomization of traditional Chinese medicine decoction^[7-12]。

Xufei, Shenyan plum, etc^[9,10]The use of the Shuanghuanglian injection for ultrasonic atomization treatment of chronic pharyngitis patients has experience of ultrasonic atomization treatment of the extracted liquid medicine in the clinical process, wherein the total effective rate of a treatment group is up to 97.5 percent in the treatment of the patients with chronic pharyngitis through ultrasonic atomization of the Shuanghuanglian injection. Zhao Yujuan and He Miao^[13,14]The seven-ingredient throat-clearing aerosol and the three-volt patch are respectively used for carrying out correlation research on the chronic pharyngitis, and the satisfactory clinical curative effect is obtained. Besides, there are warm wood^[15]The ginger juice is mixed with the mixed powder of the euphorbia kansui, the asarum, the white mustard seed and the like to form the ointment, and the effect is also satisfactory in the application research of plaster cultivation, Tiantu point, Dazhui and Feishu application.

The non-bacterial inflammation is the cause of pharyngitis, has the clinical characteristics of stubborn symptoms, long lingering and difficult-to-cure course and the like, and can directly influence the life and work of people. Western medicine treatment is widely applied in clinic, but mainly takes antibiotic medicines, sometimes the curative effect is not obvious, and some serious side effects can be caused; the traditional Chinese medicine in China is obviously different from western medicine, and focuses on the overall disease and emphasizes dialectical treatment methods, so that the treatment effect is more satisfactory, and the side effect is small^[8-11]. However, the application of the traditional Chinese medicine preparation in clinical practice is relatively limited, and a large-scale experiment for treating pharyngitis in traditional Chinese medicine is lacked, so more scientific clinical research is needed.

Pharyngitis, which is characterized by repeated attack and prolonged course of disease, often brings adverse effects on daily life, study and work of patients, and causes great trauma to physical and mental health of patients. The chronic condition development, pharyngeal mucosa and submucosal microcirculation system are often stimulated by inflammatory factors, the tissues can be anoxic, metabolic disturbance and glandular secretion disorder can occur, and chronic stimulation continuously stimulates pharyngeal nerve endings, so the condition of the patients is gradually aggravated, and the use of antiviral and antibiotic medicines in clinic can not achieve satisfactory treatment effect^[9-13]。

The novel coronavirus pneumonia (Corona Virus Disease 2019, COVID-19) belongs to the category of epidemic diseases from the perspective of Chinese medicine. The pneumonia patients infected by the novel coronavirus have the main clinical manifestations of fever, hypodynamia and dry cough, and all show certain symptoms of pharyngeal inflammation. The clinical manifestations of the patients with the mild cold-damp stagnation lung disease of the new coronary pneumonia comprise fever, hypodynamia, cough, expectoration and the like, and the clinical manifestations of the patients with the damp-heat stagnation lung disease also comprise dry cough, little phlegm and pharyngalgia.

The ancient Chinese medical record of "tea is a medicine for treating diseases. The research shows that the tea contains the ammonia theophylline, the tea polyphenol, the caffeine, the theophylline, the theobromine and the like, has the effects of treating and protecting health for a plurality of diseases, and particularly has the effects of reducing blood pressure, preventing and treating arteriosclerosis, resisting radiation, preventing cancer, helping digestion, relieving fatigue and the like^[16]. Although tea has many pharmacological actions of traditional Chinese medicines, the effective action is very little.

Tea culture is an important component of the traditional culture of China. From ancient times to present, the health care tea has positive influence on life and health care of people. The medicinal tea, namely the tea agent, is an important member of the traditional Chinese medicine treasury, and is popular like drinking tea, and the tea and the Chinese herbal medicines are brewed or decocted for drinking, so that the aim of daily disease prevention is fulfilled. The Guangya of the ancient medical books Zhang Yuan, the Song of Sunzhu, the Shennong's herbal notes of the pottery Hongjing, the Qianjin key prescription of the Sun Si, the Waitai secret of the Wang boil all have descriptions of the selection and action of the herb tea, and many new prescriptions of the herb tea appear in order to drink the health-care herbs from Hou to civilians up to the emperor^[16,18]。

The bagged Chinese medicine tea is prepared through processing tea into coarse powder, packing in paper bag, soaking in boiling water to eliminate dregs and drinking liquid medicine. The traditional Chinese medicine powder is developed from ancient Chinese medicine powder boiling and drinking agents, and has the effects of benefiting qi, assisting exhaustion, regulating yin and yang, removing evil, washing viscera and caring skin. The bagged steeping drug has large dosage, small volume, convenient taking and quick dissolution, furthest retains the advantages and characteristics of the traditional decoction, is more close to the living habits of the masses, effectively develops the traditional decoction excessively and invisibly into the mainstream of the popular drug dosage form^[17,19]。

The traditional Chinese medicine bagged steeping preparation is firstly researched in Japan in the 70 th century in 20 th century, Chinese also has special research on the traditional Chinese medicine bagged steeping preparation in the 80 th century in 20 th century, particularly more detailed research on the aspects of preparation process, effective leaching rate, pharmacological action, clinical application and the like of the traditional Chinese medicine bagged steeping preparation is carried out, and blood pressure reducing tea bags, eight-treasure tea bags, Sichuan peony tea bag and the like are recorded in drug Standard of Ministry of public health of the people's republic of China^[18]。

In the actual tea bag, due to the consideration of use and economic value, the tea leaves are beaten into fan-shaped fragments to form a basic flow, which is in conflict with the aesthetic concept of famous tea, even if part of the tea bag is packaged by the tea bag, the tea bag is only required by overseas markets, and the development of the tea bag in the Chinese market is limited to a great extent^[19-21]. The original tea bag which does not break the tea and keeps the original shape of the tea seems to better meet the requirements of consumers in China.

The preparation process of the bagged steeping drug is simple, can keep effective components as much as possible, has the characteristics of high leaching rate, quick response, convenient taking and the like, and in recent years, the method for improving the leaching rate of the effective components of the medicinal materials is more and more emphasized, so that the research on special preparation processes is gradually increased, the quality and quantity are optimized, and the satisfactory result is obtained.

In order to seek a new method for treating pharyngitis, in particular pharyngitis and other symptoms and/or symptoms caused by novel coronavirus pneumonia, the life quality of a patient is improved, in particular the relapse of chronic pharyngitis is controlled, and the traditional Chinese medicine external treatment method is started to be used clinically. In addition, considering that the common traditional Chinese medicine method is simple and easy, the misuse and abuse of antibiotic medicines can be effectively reduced, the adverse reaction is reduced, the long-term effect is satisfactory, and the Chinese medicinal preparation is worthy of being popularized and used in clinic.

Disclosure of Invention

The inventor obtains a pharmaceutical composition through intensive research and creative work, and surprisingly discovers that the pharmaceutical composition has the effects of nourishing yin and relieving sore throat, tonifying qi and moistening lung, clearing throat and relieving sore throat, removing dirt and eliminating turbidity and the like, and can effectively treat and/or prevent pharyngitis, particularly pharyngitis caused by novel coronavirus pneumonia (Corona Virus Disease 2019, COVID-19); can effectively eliminate phlegm, and is particularly used for eliminating phlegm for patients with novel coronavirus pneumonia; and/or can be effective in relieving cough, particularly in patients with new coronavirus pneumonia.

The following invention is thus provided:

one aspect of the present invention relates to a pharmaceutical composition comprising:

in some embodiments of the invention, the pharmaceutical composition comprises:

in some embodiments of the present invention, the unit dose of the pharmaceutical composition is 2 to 10g, preferably 3 to 5g, and more preferably 3 g.

In some embodiments of the invention, the pharmaceutical composition is a tea; preferably, it is packaged in the form of a teabag.

In some embodiments of the invention, the pharmaceutical composition is pulverized or not pulverized; preferably pulverized; preferably, the pulverized medicinal powder passes through a No. 1 sieve; more preferably, the pulverized powder passes through a No. 1 sieve and cannot pass through a No. 5 sieve.

In some embodiments of the invention, the pharmaceutical composition has a water content of less than 12%; preferably, less than or equal to 10%, or less than or equal to 8%; more preferably, less than or equal to 6%, or less than or equal to 5%.

In some embodiments of the invention, the pharmaceutical composition comprises:

the composition principle of the prescription is firstly seen in the Suwen-Zhi-Zhen-Yao university treatise on 'the principle that the principal disease is monarch, the assistant is monarch and the assistant is guide'. The principle of the prescription is enriched and expanded by doctors of all generations on the basis.

1. Monarch drug

It is a drug that has a main therapeutic effect on major diseases or major symptoms, i.e., it is designed to target at the main etiology, leading pathogenesis or major symptoms of the disease, and it is the core part of the prescription composition. Monarch drugs generally have the characteristics of stronger potency, less medicinal taste and relatively larger dosage. "major is the principal" means relative to the conventional dosage of the drug itself, rather than the absolute dosage in the formulation compared to other drugs, e.g., limited by the texture, quality and toxicity of the drug itself, e.g., lighter in light floral leaf type; the dosage of heavy materials such as shells is heavy; the dosage of the medicinal materials with strong quality and strong power is preferably small, otherwise, the dosage can be slightly large; the toxic herbs such as Wu Tou are used in small dosage even as monarch drugs.

2. Ministerial drug

The ministerial drugs have two layers: 1) auxiliary monarch drug for strengthening the drugs for treating the major diseases or the major symptoms; 2) the medicine has main treatment effect on accompanied diseases or concurrent symptoms. The medicine has more medicinal flavor than the monarch drug, and the potency and the dosage of the medicine are smaller than those of the monarch drug.

3. Adjuvant drug

The adjuvant has three layers: 1) adjuvant drugs, i.e., drugs that combine monarch and ministerial drugs to enhance therapeutic effects, or drugs that directly treat secondary symptoms; 2) adjuvant drugs, which refer to drugs that eliminate or relieve the toxicity and side effects of monarch and ministerial drugs; 3) the anti-adjuvant drugs are the drugs with the property of being opposite to that of the monarch drugs and playing the role of the other drugs in the treatment when the drugs reject the disease.

4. Medicine for taking care of the drugs

The guiding drugs have two meanings: 1) the channel-guiding medicine can guide the efficacy of the traditional Chinese medicine to directly reach the focus; 2) the harmonizing herbs can harmonize the properties of the herbs in the recipe, coordinate the interaction of the herbs or correct the taste. The dosage of the drug is small and the number of the drugs is small.

Without being bound by theory, the inventors speculate one possibility as follows:

radix Pseudostellariae and green tea are used as principal drugs;

lotus leaf, mint, folium isatidis, fructus forsythiae, burdock and rhizoma cimicifugae, which can raise the clear and descend the turbid, clear the throat and relieve sore throat, are used as ministerial drugs;

radix Paeoniae Rubra and radix Ophiopogonis as adjuvant drugs;

licorice root, radix Glycyrrhizae coordinates the effects of the other drugs in the recipe (guiding drugs).

In some embodiments of the present invention, the pharmaceutical composition is composed of the above herbs in parts by weight.

In some embodiments of the present invention, the pharmaceutical composition further comprises one or more pharmaceutically acceptable excipients.

In some embodiments of the present invention, the pharmaceutical composition is composed of the above herbs in parts by weight and one or more pharmaceutically acceptable excipients.

The term "excipient" refers herein to an excipient or vehicle used to administer the primary drug, including, but not limited to, diluents, disintegrants, precipitation inhibitors, surfactants, glidants, binders, lubricants, coating materials, and the like. Adjuvants are generally described in "Remington's Pharmaceutical Sciences" by e.w. martin. Examples of adjuvants include, but are not limited to, aluminum monostearate, aluminum stearate, carboxymethylcellulose, sodium carboxymethylcellulose, crospovidone, glyceryl isostearate, glyceryl monostearate, hydroxyethyl cellulose, hydroxymethyl cellulose, hydroxyeicosateyl hydroxystearate, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, lactose monohydrate, magnesium stearate, mannitol, microcrystalline cellulose, and the like.

In some embodiments of the invention, the pharmaceutical composition wherein, per 3g of the pharmaceutical composition:

the content of paeoniflorin is more than or equal to 5.78 mug,

the content of liquiritin is more than or equal to 2.78 mug,

glycyrrhizic acid content is more than or equal to 4.30 mu g, and/or

The arctiin content is not less than 16.00 mu g;

preferably, the first and second electrodes are formed of a metal,

the content of paeoniflorin is more than or equal to 6 mug,

the content of liquiritin is more than or equal to 2.8 mug,

glycyrrhizic acid content is more than or equal to 4.5 microgram, and/or

The arctiin content is more than or equal to 18 mu g;

more preferably still, the first and second liquid crystal compositions are,

the content of paeoniflorin is more than or equal to 7 mug,

the content of liquiritin is more than or equal to 3 mug,

glycyrrhizic acid content is more than or equal to 5 microgram, and/or

The arctiin content is not less than 19 μ g.

The pharmaceutical composition of the invention is also called squareness tea.

In some embodiments of the invention, the pharmaceutical composition is for use as described in any one of 1) to 4) selected from the group consisting of:

1) replenishing qi, moistening lung, clearing throat, relieving sore throat and/or removing dirt and turbid;

2) treating and/or preventing pharyngitis; preferably, the pharyngitis is chronic pharyngitis; preferably, the pharyngitis is pharyngitis caused by novel coronavirus pneumonia (Corona Virus Disease 2019, COVID-19);

3) expectorant, preferably for patients with novel coronavirus pneumonia (Corona Virus Disease 2019, COVID-19);

4) cough relief, preferably for patients with novel coronavirus pneumonia (Corona Virus Disease 2019, COVID-19).

Another aspect of the present invention relates to an extract which is an aqueous or ethanolic solution of the pharmaceutical composition of any of the present invention. Preferably, the temperature of the water is greater than or equal to 80 ℃, greater than or equal to 85 ℃, greater than or equal to 90 ℃ or greater than or equal to 95 ℃.

A further aspect of the invention relates to the use of a pharmaceutical composition according to any one of the invention or an extract according to the invention for the manufacture of a medicament selected from any one of (1) to (4) as follows:

(1) a medicine for tonifying qi, moistening lung, clearing throat, relieving sore throat and/or removing dirt and turbid pathogen;

(2) a medicament for the treatment and/or prevention of pharyngitis; preferably, the pharyngitis is chronic pharyngitis; preferably, the pharyngitis is pharyngitis caused by novel coronavirus pneumonia (Corona Virus Disease 2019, COVID-19);

(3) an expectorant, preferably a drug for expectoration in patients with novel coronavirus pneumonia (Corona Virus Disease 2019, COVID-19);

(4) the cough relieving medicine is preferably used for relieving cough of patients with novel coronavirus pneumonia (Corona Virus Disease 2019, COVID-19).

Yet another aspect of the present invention relates to a method selected from any one of (1) to (4) below:

(1) a method for tonifying qi, moistening lung, clearing throat, relieving sore throat and/or removing dirt and turbid pathogen;

(2) methods of treating and/or preventing pharyngitis; preferably, the pharyngitis is chronic pharyngitis; preferably, the pharyngitis is pharyngitis caused by novel coronavirus pneumonia (Corona Virus Disease 2019, COVID-19);

(3) a method of eliminating phlegm, preferably, a method of eliminating phlegm for patients with novel coronavirus pneumonia (Corona Virus Disease 2019, COVID-19);

(4) a method of relieving cough, preferably, a method of relieving cough for patients with novel coronavirus pneumonia (Corona Virus Disease 2019, COVID-19);

comprising the step of administering to a subject in need thereof an effective amount of a pharmaceutical composition according to any of the invention or an extract according to the invention.

In some embodiments of the invention, the method comprises the steps of:

the tea is infused 1 bag each time, 2-3 times per day.

The term "effective amount" refers to a dose that achieves treatment, prevention, alleviation and/or amelioration of a disease or disorder described herein in a subject.

Nourishing yin, also known as nourishing yin, tonifying yin, nourishing yin and tonifying yin. Belongs to the complementary method.

Relieving sore throat refers to a method of relieving sore throat by eliminating pathogenic factors and strengthening body resistance, and treating throat diseases.

Yet another aspect of the present invention relates to a method for preparing a pharmaceutical composition according to any one of the present invention, comprising the steps of:

(1) pulverizing the medicinal materials, and sieving with No. 1 sieve and No. 5 sieve to obtain coarse powder between No. 1 sieve and No. 5 sieve; preferably, the No. 1 oversize powder is crushed again and passes through the No. 1 sieve and the No. 5 sieve to obtain coarse powder between the No. 1 sieve and the No. 5 sieve, and the coarse powder is combined with the coarse powder obtained in the previous step;

(2) uniformly mixing the obtained coarse powder;

(3) packaging and sterilizing;

preferably, in the step (1), radix ophiopogonis and rhizoma cimicifugae are crushed together, and/or fructus arctii and radix paeoniae rubra are crushed together; preferably, the remaining medicinal materials are pulverized separately or together.

Yet another aspect of the present invention relates to a method for quality control or quality control of the pharmaceutical composition according to any one of the present invention, comprising the step of detecting the contents of paeoniflorin, liquiritin, glycyrrhizic acid and arctiin, wherein, calculated per 3g of the pharmaceutical composition,

if so:

the content of paeoniflorin is more than or equal to 5.78 mug,

the content of liquiritin is more than or equal to 2.78 mug,

glycyrrhizic acid content of not less than 4.30 μ g, and

the arctiin content is not less than 16.00 mug,

the quality of the pharmaceutical composition is qualified;

preferably, if:

the content of paeoniflorin is more than or equal to 6 mug,

the content of liquiritin is more than or equal to 2.8 mug,

glycyrrhizic acid content of not less than 4.5 μ g, and

the arctiin content is more than or equal to 18 mug,

the quality of the pharmaceutical composition is qualified;

more preferably, if:

the content of paeoniflorin is more than or equal to 7 mug,

the content of liquiritin is more than or equal to 3 mug,

glycyrrhizic acid content is more than or equal to 5 mug, and

the arctiin content is not less than 19 mug,

the quality of the pharmaceutical composition is qualified;

preferably, the contents of paeoniflorin, liquiritin, glycyrrhizic acid and arctiin are detected by high performance liquid chromatography;

preferably, the chromatographic conditions are as follows:

a chromatographic column: cosmosil C₁₈A chromatographic column;

mobile phase: acetonitrile (a) and 0.2% aqueous phosphoric acid (B);

flow rate: 1.0 mL/min^-1；

Wavelength: 232 nm;

sample introduction amount: 10 mu L of the solution;

column temperature: 30 ℃;

gradient elution procedure: 0-10 min, 10% -20% A; 10-18 min, 20% -25% A; 18-25 min, 25% -38% A; 25-30 min, 38% -43% A; 30-40 min, 43% -50% A; 40-43 min, 50-95% A.

Advantageous effects of the invention

The pharmaceutical composition of the present invention achieves the technical effects described in any one or more of the following items (1) to (5):

(1) nourishing yin and relieving sore throat;

(2) replenishing qi, moistening lung, clearing throat, relieving sore throat, removing dirt, and eliminating turbid pathogen;

(3) can effectively treat and/or prevent pharyngitis, in particular pharyngitis caused by novel coronavirus pneumonia (Corona VirusDisease 2019, COVID-19);

(4) can effectively eliminate phlegm, and is particularly used for eliminating phlegm for patients with novel coronavirus pneumonia; and

(5) can effectively relieve cough, and is particularly suitable for patients with novel coronavirus pneumonia to relieve cough.

Drawings

FIG. 1: thin layer chromatogram of radix Paeoniae Rubra. From left to right: 1-3 are samples of 3 batches, 4 is a red peony root control medicinal material, 5 is a paeoniflorin control, and 6 is a red peony root lack negative control.

FIG. 2: DPPH standard curve.

FIG. 3: and (5) inspecting the DPPH inhibition effect of the sample.

FIG. 4: results of the Vc on DPPH inhibition.

FIG. 5: the result of the DPPH inhibition effect of green tea 1 was examined.

FIG. 6: the result of the investigation of DPPH inhibition effect of green tea 2.

FIG. 7: the inhibition effect of BHT on DPPH is observed.

FIG. 8: and (5) comparing the bacteriostasis of the test sample on staphylococcus aureus.

FIG. 9: and (5) comparing the test sample for inhibiting bacteria of escherichia coli.

FIG. 10: phenol red standard curve.

Detailed Description

Embodiments of the present invention will be described in detail below with reference to examples, but those skilled in the art will appreciate that the following examples are only illustrative of the present invention and should not be construed as limiting the scope of the present invention. The examples, in which specific conditions are not specified, were conducted under conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products commercially available.

Preparation example 1: preparation of bag-packed tea for nourishing Yin and relieving sore throat (batch No. 20170726)

Prescription:

the medicinal materials are fed according to the prescription proportion, the total amount of 1000 prescriptions is 91kg, decoction pieces are coarsely crushed, a screen of a crusher selects a No. 1 screen, the radix ophiopogonis, the rhizoma cimicifugae, the burdock and the red peony root are respectively mixed and crushed according to the proportion in the prescription, and the rest medicinal materials can be independently crushed or mixed and crushed to obtain 87.3kg of medicinal powder. Sieving the obtained medicinal powder with a No. 1 sieve (10 meshes) and a No. 5 sieve (80 meshes) (sieving the powder on the No. 1 sieve for coarse crushing and sieving again), retaining 82.6kg of coarse powder between the No. 1 sieve and the No. 5 sieve, putting the obtained coarse powder into a mixer for total mixing (the purpose of total mixing is to uniformly mix all medicinal material powder) for 30 minutes, packaging by adopting heat-sealing type tea filter paper, packaging by 3 g/bag 6 bags/bag, irradiating for sterilization, and packaging in an outer packaging bag to obtain the 4407 packaging finished product. Lot number 20170726.

Preparation example 2: preparation of bag-packed tea for nourishing Yin and relieving sore throat (batch No. 20170802)

The medicinal materials are fed according to the prescription proportion, the total amount of 1000 prescriptions is 91kg, decoction pieces are coarsely crushed, a screen of a crusher selects a No. 1 screen, the radix ophiopogonis, the rhizoma cimicifugae, the burdock and the red peony root are respectively mixed and crushed according to the proportion in the prescription, and the rest medicinal materials can be independently crushed or mixed and crushed to obtain 87.7kg of medicinal powder. Sieving the obtained medicinal powder with a No. 1 sieve (10 meshes) and a No. 5 sieve (80 meshes) (pulverizing the powder on the No. 1 sieve for coarse sieving again), retaining 83.0kg of coarse powder between the No. 1 sieve and the No. 5 sieve, placing the obtained coarse powder into a mixer for total mixing for 30 minutes, packaging by adopting heat-sealing type tea filter paper, 3 g/bag by 6 bags/bag, irradiating for sterilization, and packaging in an outer packaging bag to obtain a 4580-packaged finished product. Lot number 20170802.

Preparation example 3: preparation of bag-packed tea for nourishing Yin and relieving sore throat (batch No. 20170813)

The medicinal materials are fed according to the prescription proportion, the total amount of 1000 prescriptions is 91kg, decoction pieces are coarsely crushed, a crusher screen adopts a No. 1 sieve, the radix ophiopogonis, the rhizoma cimicifugae, the burdock and the red peony root are respectively mixed and crushed according to the proportion in the prescription, and the rest medicinal materials can be independently crushed or mixed and crushed to obtain 88.1kg of medicinal powder. Sieving the obtained medicinal powder with a No. 1 sieve (10 meshes) and a No. 5 sieve (80 meshes) (pulverizing the powder on the No. 1 sieve for coarse sieving again), retaining 83.2kg of coarse powder between the No. 1 sieve and the No. 5 sieve, placing the obtained coarse powder into a mixer for total mixing for 30 minutes, packaging by adopting heat-sealing type tea filter paper, 3 g/bag by 6 bags/bag, irradiating for sterilization, and packaging in an outer packaging bag to obtain 4593 packaged finished product. Lot number 20170813.

The prescription composition and preparation process of 3 batches of the formula Guancha (yin nourishing and sore throat relieving tea bag) prepared in the preparation examples 1-3 are the same.

Experimental example 1: quality detection and control

Thin-layer chromatography (TLC) is adopted for qualitative identification of radix Paeoniae Rubra (radix Paeoniae Rubra is one of quantitative components, and quality control is facilitated) which is one of the main medicines in the formula for nourishing yin and relieving sore throat, and High Performance Liquid Chromatography (HPLC) is adopted for content determination of the main components of GUANGUAN tea. According to the tea standard (2015 edition of Chinese pharmacopoeia, the fourth general rule of tea 0188), the comprehensive quality standard research is carried out on the Guancha, and scientific and effective basis is provided for the further research of hospital preparations.

1 materials and methods

1.1 materials and reagents

1.1.1 instruments

1.1.2 reagents and materials

1.1.3 reference

Control for content measurement: paeoniflorin (purity not less than 98%, batch No. 1129a02), arctiin (purity not less than 98%, batch No. 1026a021) were purchased from Solarbio; glycyrrhiza glycoside (purity is more than or equal to 98%, batch No. 11610-201106) and ammonium glycyrrhizinate (purity is more than or equal to 93.1%, batch No. 110731-201418) were purchased from China food and drug testing research institute.

Identifying reference medicinal materials: great burdock achene (batch No. 120903-201510) and red peony root (121093-201303) were purchased from the institute of food and drug testing, China.

1.1.4 samples

Three batches of the Guancha tea (20170726, 20170802 and 20170813) prepared in preparation examples 1 to 3 were prepared in the same manner, and each batch of samples of the red peony lacking was prepared as a negative control.

The negative control was prepared in the same manner as in preparation examples 1-3, except that it contained no radix Paeoniae Rubra. The purpose of setting a negative sample is to prove that the identification method of the red paeony root in the Guancha is reliable, which indicates that the Guancha really has characteristic spots of paeoniflorin in the red paeony root and other medicinal materials except the red paeony root do not have paeoniflorin.

1.2 methods

1.2.1 thin layer identification

1.2.1.1 thin layer identification of Red peony root

(1) Preparation of test article and negative test article solution

Taking 2g of the medicinal powder of the Guancha tea, adding 40mL of ethanol, shaking and filtering, evaporating the filtrate to dryness, and adding 5mL of ethanol into residues to dissolve the residues to obtain a test solution. 3 batches of samples were prepared in the same manner.

Taking the Guancha sample negative control, and preparing a negative control solution by the same method.

(2) Preparation of reference drug solution

Taking 0.5g of radix Paeoniae Rubra reference material, and making into reference material solution by the same method as in item 1.2.1.1 (1).

(3) Preparation of control solution

Collecting penoniflorin control 2mg, adding ethanol to obtain control solution (2 mg. mL)^-1)。

(4) Thin layer chromatography development conditions

Thin-layer plate: silica gel G thin layer plate

Sample amount of spotting: mu.L of each solution

Developing agent: chloroform-ethyl acetate-methanol-formic acid (40:5:10:0.2)

Color developing agent: 5% vanillin sulfuric acid solution, heating at 105 deg.C for color development

1.2.2 examination

The inspection was carried out according to the general rule of tea 0188 of the fourth part of the 2015 edition of Chinese pharmacopoeia.

1.2.2.1 moisture determination

The measurement was carried out according to the method of measuring moisture (general rule 0832) in the fourth part of the "Chinese pharmacopoeia" of the 2015 edition.

1.2.2.2 filling difference

Taking 3 batches of the square crown tea prepared in the preparation example 1, 10 bags of each batch, checking according to a method of 'filling quantity difference' under the item 0188 of the fourth general regulation of tea in 2015 edition of Chinese pharmacopoeia, the product is 3g, and the filling quantity difference is +/-12%.

1.2.2.3 microbial Limit

3 batches of the Guancha tea are taken, 3 bags are taken for each batch, and the microbial limit method is checked according to the rule of 0188 in the fourth general guideline of the 2015 edition of Chinese pharmacopoeia.

1.2.3 assay

Three batches of the square crown tea samples are taken, 3 parts of each sample, and each sample is 3 g.

Sample preparation: putting 3g of a sample in a beaker, adding 180mL of pure water with the temperature of 85 ℃, and soaking for 30 min; adding methanol into the sample, performing ultrasonic treatment for 30min, cooling, transferring to a centrifuge tube, centrifuging at room temperature for 15min (5000rpm), transferring the supernatant to a 10mL volumetric flask, adding 90% methanol to a constant volume, shaking up, and filtering with a 0.45 μm microporous membrane.

Chromatographic conditions are as follows: a chromatographic column: cosmosil C₁₈Chromatographic column (4.6mm × 250mm, 5 μm), mobile phase acetonitrile (A) and 0.2% phosphoric acid water solution (B), flow rate 1.0mL min^-1(ii) a Wavelength: 232 nm; sample introduction amount: 10 mu L of the solution; column temperature: at 30 ℃. Gradient elution procedure: 0-10 min, 10% -20% A; 10-18 min, 20% -25% A; 18-25 min, 25% -38% A; 25-30 min, 38% -43% A; 30-40 min, 43% -50% A; 40-43 min, 50-95% A; the theoretical plate number is not less than 6000 calculated according to the paeoniflorin peak.

2 results of the experiment

2.1 thin layer identification results

The results of the thin layers are shown in FIG. 1. As can be seen from FIG. 1, the three batches of the Guancha tea samples all have characteristic spots of paeoniflorin, and the negative samples without radix Paeoniae Rubra have no characteristic spots of paeoniflorin, which indicates that the method can be used for identifying radix Paeoniae Rubra in Guancha tea.

2.2 general rule of tea

2.2.1 moisture test results

As shown in table 1.

Table 1: water content test results

As can be seen from Table 1, the water content is lower than 12%, which meets the requirement of tea.

2.2.2 Loading Difference test results

As shown in table 2.

Table 2: result of load check

As can be seen from Table 2, the difference of the filling amount is within + -12%, which meets the requirement of tea.

2.2.3 results of microbial examination

The microbial detection results of 3 batches of samples meet the regulations.

2.3 results of content measurement

The content was calculated by the external standard method and averaged, and the results are shown in table 3.

Table 3: results of three-batch sample content measurement (n ═ 3)

4 components of paeoniflorin, liquiritin, glycyrrhizic acid and arctiin can be selected as indexes of quality control. Considering the influence of the source, processing technique and detection error of the medicinal materials, the lower limit of the mass can be 20% of the average value of the 3 samples in table 3, the content of paeoniflorin is more than or equal to 5.78 mug, the content of liquiritin is more than or equal to 2.78 mug, the content of glycyrrhizic acid is more than or equal to 4.30 mug, and the content of arctiin is more than or equal to 16.00 mug.

Experimental example 2: antioxidant activity

Here, the antioxidant activity of the crown tea (sample of lot 20170726 obtained in preparation example 1) was examined by eliminating DPPH radical. DPPH free radical scavenging method is a method for scavenging dibenzo bitter acyl, DPPH free radical methanol solution is purple, the maximum absorption wavelength is 517nm, if other substances provide an electron to make lone pair electrons pair, the absorbance is reduced, and the solution color is lightened. The degree of this change is linear with the degree of radical scavenging, and thus this method can be used to represent the radical scavenging ability of a substance, usually IC₅₀The value is expressed as the concentration, IC, of the sample required for 50% DPPH radical scavenging₅₀The smaller the value, the stronger the ability of the sample to scavenge DPPH free radicals and the stronger the antioxidant capacity^[14,15]。

1 materials and methods

1.1 materials

1.1.1 Experimental instruments

1.1.2 reagents

Name of the manufacturer

Cascada, Pall USA ultrapure Water^TMUltrapure water machine

Kancoded science and technology Co., Ltd, Tianjin, Anhydrous ethanol

1.1.3 samples

DPPH (1, 1-diphenyl-2-trinitrophenylhydrazine) and BHT (2, 6-di-tert-butyl-p-cresol) are purchased from New pharmaceutical research center in Tianjin, VC is purchased from Shanghai-sourced leaf Biotech limited, green tea 1 is produced from Xinyang Maojian tea in Henan, and green tea 2 is produced from green tea manufactured by laboratories.

2 results of the experiment

2.1 preparation of the solution

2.1.1 preparation of DPPH solution

Accurately weighing a volume flask containing DPPH reagent 7.88mg to 100mL, dissolving with ethanol to a constant volume, wherein the concentration is 2 × 10^-4And (5) mol/L, shaking uniformly, and placing in a refrigerator for refrigeration for later use.

2.1.2 preparation of samples and Green tea

Mixing with sample and green tea at ratio of 10:1(mL: g) with boiling water, ultrasonic extracting for 30min, collecting supernatant, repeating the above operation twice for the rest residue, and mixing the supernatants to obtain crude extract. Respectively preparing 6 sample solutions with different concentrations, wherein the concentrations are as follows: 0.2 mg/mL^-1、0.175mg·mL^-1、0.15mg·mL^-1、0.125mg·mL^-1、0.1mg·mL^-1、0.05mg·mL^-1。

2.1.3 preparation of control

Control 1: precisely weighing BHT, adding absolute ethyl alcohol to prepare the following components in concentration: 0.2 mg/mL^-1、0.175mg·mL^-1、0.15mg·mL^-1、0.125mg·mL^-1、0.1mg·mL^-1、0.05mg·mL^-1The solution of (1).

Control 2: precisely weighing Vc, adding pure water to prepare the following concentrations: 0.2 mg/mL^-1、0.175mg·mL^-1、0.15mg·mL^-1、0.125mg·mL^-1、0.1mg·mL^-1、0.05mg·mL^-1The solution of (1).

2.1.4 drawing of DPPH Standard Curve

Diluting by stepwise dilution method to prepare DPPH solution with six concentration gradients, fixing volume with anhydrous ethanol, and measuring absorbance of each solution at 519nm with microplate reader using anhydrous ethanol as blank. The concentration is used as an abscissa and the absorbance is used as an ordinate, a standard curve is drawn, the result is shown in FIG. 2, and the regression equation of the DPPH concentration and the absorbance A is as follows: y is 0.0019X +0.2084, and correlation coefficient R²0.9997, DPPH 49.8-308 mug/mL^-1The concentration range has a good linear relationship.

2.1.5 comparison of the ability of samples, Green tea, BHT, Vc to scavenge free radicals

1mL of 2 × 10 was added^-4mol·L^-1Mixing the DPPH absolute ethyl alcohol solution with 5 samples with different mass concentrations, green tea, BHT and Vc solution to be detected, placing the mixture in a 96-well plate, shaking the mixture evenly, reacting the mixture in a dark room for 30min at room temperature, adjusting the absolute ethyl alcohol to zero, taking Vc and BHT as positive controls, and measuring the absorbance (A) at the wavelength of 517nm by using an enzyme labeling instrument₁) And simultaneously measuring the absorbance of a mixture of 1mL of the solution to be measured and 1mL of anhydrous ethanol (A)₂) Absorbance of a mixture of 1mL of absolute ethanol and 1mL of a DPPH ethanol solution (A)₀) See table 4. Each group was assayed in triplicate and the average was taken to calculate the DPPH radical clearance of the samples.

The calculation formula is as follows: clearance (%) - (1- (A)₁-A2)/A₀]×100％

Table 4: DPPH experiment sample adding table

Absorbance value	Sample addition amount
		Blank A0	1mL 0.2mmol·L-1DPPH-ethanol solution +1mL of blank solvent
A1	1mL 0.2mmol·L-1DPPH-ethanol solution +1mL of solution to be tested
		A2	1mL of ethanol solution and 1mL of solution to be detected

Experimental data were analyzed using GraphPad Prism software. The concentration of radical scavenger at 50% DPPH radical inhibition, i.e. IC, was calculated₅₀. The results of the inhibition of DPPH by the samples are shown in Table 5 and FIG. 3.

Table 5: examination result of DPPH inhibition effect of sample

The results of the inhibition of DPPH by Vc are shown in Table 6 and FIG. 4.

Table 6: results of investigation of inhibition of DPPH by Vc

The results of the DPPH inhibition assay of green tea 1 are shown in table 7 and fig. 5.

Table 7: investigation result of DPPH inhibition effect of green tea 1

The results of the DPPH inhibition by green tea 2 are shown in table 8 and fig. 6.

Table 8: investigation result of inhibition effect of green tea 2 on DPPH

The results of the inhibition of DPPH by BHT are shown in Table 9 and FIG. 7.

Table 9: investigation result of inhibition effect of BHT on DPPH

3 small knot

The antioxidant concentration by mass at 50% clearance is generally chosen as the index for the evaluation of the oxidation resistance, IC₅₀The smaller the value, the stronger the antioxidant's ability to scavenge free radicals. Calculating IC of sample, Vc, green tea 1, green tea 2 and BHT according to linear relation between clearance and antioxidant mass concentration₅₀The values were 0.01244 mg. multidot.mL respectively^-1、0.03090mg·mL^-1、0.04591mg·mL^-1、0.06048mg·mL^-1、0.07407mg·mL^-1Their DPPH scavenging capacity was in the order of > Vc > Green tea 1 > Green tea 2 > BHT.

As can be seen from FIGS. 2 to 6, all the samples tested had good ability to scavenge DPPH free radicals, and the antioxidant effect was increased with increasing concentration. The tea bag for nourishing yin and relieving sore throat has better antioxidant capacity and higher free radical scavenging capacity than that of common green tea, and is closely related to active ingredients contained in the tea bag, so that a new theoretical support is provided for the tea bag for nourishing yin to play the roles of clearing heat, nourishing yin and relieving sore throat.

Experimental example 3: study of in vitro bacteriostatic Activity

By comparing the gram-positive bacteria represented by staphylococcus aureus and gram-negative bacteria in vitro bacteriostasis of escherichia coli of the sample and green tea, namely by a medicament double dilution method and a colony meterA method combining a plurality of methods comprises the steps of carrying out in-vitro antibacterial activity research on a sample by using staphylococcus aureus and escherichia coli tested strains, screening out antibacterial activity, and comparing the minimum antibacterial concentration of the sample and green tea, thereby determining the strength of the antibacterial activity^[16-18]. Provides a theoretical basis for the activity research of the Fangguan tea.

1 materials and methods

1.1 Experimental instruments

1.2 reagents

1.3 strains

Staphylococcus aureus (Staphylococcus aureus) and Escherichia coli (Escherichia coli) were provided by Microbiol laboratories of Tianjin university of medicine; cefradine for injection is produced by zilu pharmaceutical co.

1.4 Experimental drugs

The sample (batch 20170726) prepared from the above preparation example 1, green tea 1 was the same as the above experimental example 2.

2 results of the experiment

2.1 preparation of the Medium, the bacterial suspension and the test liquid

2.1.1 preparation of the Medium

Adding distilled water into the nutrient agar culture medium according to the proportion of adding 1L of water into each 32g of nutrient agar culture medium, heating and stirring, boiling until the solution is transparent, sterilizing at 121 ℃ for 20min under high pressure, and placing in a water bath at 48-50 ℃ for heat preservation for later use.

2.1.2 preparation of test solutions

Precisely weighing 10g of sample and green tea, ultrasonically extracting with boiling water for 30min, centrifuging (5000rpm) for 15min, collecting supernatant, and preparing 6 dilutions with concentration gradient by double dilution method.

2.1.3 preparation of the bacterial suspension

Under the aseptic condition, respectively supplyingThe test strain is inoculated into a test tube filled with a liquid culture medium from a solid culture medium for enrichment, the strain used in the test is firstly inoculated on a nutrient agar culture medium plate by adopting a scribing method, cultured for 24 hours at 37 ℃ and then stored in a refrigerator at 4 ℃. When in use, a proper amount of bacterial strains are selected by a sterilization ring and inoculated in a nutrient broth culture medium, the sterilized LB culture medium is taken, staphylococcus aureus and escherichia coli are added into a shaking table for 16h (the rotating speed is 150, the temperature is 37 ℃), the sterile physiological saline is used for dilution, and the sterile physiological saline is diluted into 10-degree concentration by adopting a Mach's turbidimetry method⁵CFU·mL^-1The bacterial suspension is ready for use.

2.2 drug susceptibility test

2.2.1 preparation of control Medium

Positive control group: 20 μ L of cefradine.

Blank control group: 50 μ L of physiological saline.

2.2.2 preparation of drug-sensitive Medium

And (3) sucking 1mL of diluted sample diluent by using a pipette gun respectively, quantitatively adding the diluted sample diluent into a sterile test tube containing 8mL of nutrient agar culture medium, shaking to fully mix the diluent and the culture medium uniformly, pouring the mixture into a culture dish, and slightly shaking the mixture uniformly again to prepare a drug-containing flat plate.

2.2.3 inoculum suspensions

Respectively inoculating 1.5 mu L of escherichia coli and staphylococcus aureus on the drug-containing plates, uniformly coating the drug-containing plates on the surface of a culture medium by using a coater, inverting each plate, and putting the plate into an incubator at 37 ℃ for culturing for 24 hours, wherein the minimum concentration at which bacterial colonies do not appear is taken as the Minimum Inhibitory Concentration (MIC).

2.3 results and analysis

2.3.1 comparison of bacteriostatic results of samples with the same concentration with green tea

As shown in fig. 8 and 9.

2.3.2 minimum inhibitory concentration results for samples and Green tea

Table 10: minimum Inhibitory Concentration (MIC) of sample

Note: -: the strain is not grown at all; +: the growth of the strain is inhibited; ++: the growth of the strain was not inhibited.

Table 11: minimum Inhibitory Concentration (MIC) of green tea against Staphylococcus aureus

Note: -: the strain is not grown at all; +: the growth of the strain is inhibited; ++: the growth of the strain is not inhibited

Table 12: minimum Inhibitory Concentration (MIC) of green tea against Escherichia coli

Note: -: the strain is not grown at all; +: the growth of the strain is inhibited; ++: the growth of the strain is not inhibited

2.3.3 analysis and discussion

As can be seen from fig. 8 and 9, the positive control colonies grew well, while the blank control colonies grew well, indicating that the solvent system and the medium had no effect on the growth of the bacteria. As can be seen from fig. 4-7, the colony growth of the solvent group of green tea is inhibited, while the colony count of the solvent group of sample is significantly less than that of the blank group but more than that of the green tea group, indicating that the bacteriostatic effect of the sample on staphylococcus aureus is not as good as that of the green tea and the sample with the same concentration. As can be seen from fig. 4 to 8, almost no colonies grew in the solvent group of green tea, and the number of colonies in the solvent group of the sample was larger than that in the solvent group of green tea but smaller than that in the blank group, indicating that the green tea and the sample had a relatively good inhibitory effect on escherichia coli.

As can be seen from Table 10, the minimum inhibitory concentrations of the samples against Escherichia coli and Staphylococcus aureus were 1.00 g/mL, respectively^-1And 0.50 g.mL^-1. As is clear from tables 11 and 12, the minimum inhibitory concentrations of green tea against Escherichia coli and Staphylococcus aureus were 0.25 g/mL, respectively^-1And 0.15 g.mL^-1. Sample for two kinds of bacteriaThe MIC value is larger, which indicates that the bacteriostatic effect of the sample is not as good as that of the green tea.

3 small knot

The experiments show that the Guancha tea has a certain in-vitro antibacterial effect, but the effect is not as good as that of green tea, which indicates that the preparation can achieve the effect of relieving sore throat by nourishing lung and stomach yin, promoting the production of body fluid to relieve cough and not achieving the effect of relieving sore throat by detoxification and sterilization.

Experimental example 4: research on yin nourishing and phlegm eliminating activities

The yin-nourishing and sore-throat-relieving teabag contains medicines with effective components of clearing heat, moistening dryness, nourishing yin, promoting the production of body fluid and the like, and for further proving that the preparation has the activity of nourishing yin and eliminating phlegm, a modern pharmacological model of mouse tracheal phenol red excretion is adopted.

Injecting phenol red into abdominal cavity of mouse, discharging phenol red reagent from trachea, increasing secretion function of respiratory tract if yin nourishing and sore throat relieving teabag has yin nourishing and phlegm eliminating activity, and increasing secretion of phenol red correspondingly, wherein the trachea is irrigated with sodium bicarbonate solution, lavage solution is developed, OD value is detected by spectrophotometer, and secretion of phenol red is measured^[19-22]And comparing the phlegm eliminating effect of the samples with the same concentration and green tea and samples with different concentrations.

1 materials and methods

1.1 instruments

1.2 reagents

1.3 animals

50 Kunming mice (20g), half male and female, were purchased from Beijing Hua Fukang Biotech GmbH.

1.4 reagent preparation

The blank control group is physiological saline.

Positive control: 5g of ammonium chloride is dissolved in 50mL of pure water and is subjected to ultrasonic treatment for 15min for later use.

Low concentration samples: 10g of the yin-nourishing and sore-throat-relieving tea bag powder prepared in the preparation example 1 is dissolved in 80mL of pure water, and the mixture is subjected to ultrasonic treatment and centrifugation for later use.

Green tea control: dissolving 10g of green tea bag tea powder in 80mL of pure water, performing ultrasonic treatment, and centrifuging for later use.

High concentration samples: 20g of the yin-nourishing and sore-throat-relieving tea bag powder prepared in the preparation example 1 is dissolved in 80mL of pure water, and the mixture is subjected to ultrasonic treatment and centrifugation for later use.

2 results of the experiment

2.1 drawing of phenol Red Standard Curve

Taking phenol red reagent 12.8mg in a 100mL volumetric flask, adding 5% sodium bicarbonate to a constant volume, shaking up, diluting into 5 solutions with different concentrations by 2-fold dilution method, wherein the concentration is 12.8 mug. multidot.mL respectively^-1，6.4μg·mL^-1，3.2μg·mL^-1，1.6μg·mL^-1，0.8μg·mL^-1，0.4μg·mL^-1. And (3) measuring the absorbance at 546nm, wherein the concentration of the phenol red is an abscissa, the absorbance is an ordinate, the result is shown in FIG. 10, and the standard curve equation of the phenol red is calculated as follows: y ═ 0.0122X +0.0434, R²0.9991. The phenol red reagent is 0.4-12.8 mug/mL^-1The linear relationship within the range is good.

2.2 mouse tracheal phenol Red excretion test

50 Kunming mice, each half of male and female, are divided into five groups, namely a blank control group, a positive control group, a sample low-concentration group, a sample high-concentration group and a control drug group (ammonium chloride). Administering 10 per group for one week, performing intragastric administration once every 24 hr, administering 30min after the last administration, injecting 0.5% phenol red (0.2mL/10kg) into abdominal cavity of each mouse, removing cervical vertebra after 30min, collecting a section of trachea from thyroid cartilage to trachea branch, and placing into a container containing 5% NaHCO₃Shaking in test tube to release phenol red completely, centrifuging at 3000rpm for 5min, collecting supernatant 1ml, 5% NaHCO₃Blank, 546nm for A, and comparing the difference of the phenol red excretion amount of each airway segment on the phenol red standard curve corresponding to the corresponding phenol red concentration, the results are shown in Table 13. Analysis was performed using SPSS statistical software, the experimental results are expressed as mean. + -. standard deviation, and t-test is performed as P<0.05 is statistically significant.

The secretion-increasing amount%

Table 13: influence of each group on mouse tracheal phenol Red secretion amount (Mean + -SD)

Note: compared with the normal control group, t-2.084, P <0.05, P < 0.01.

The results show that both the low concentration and high concentration groups of the samples show good expectorant efficacy, far superior to that of green tea.

Reference to the attached literature

[1] Research on chronic pharyngitis by western medicine in recent three years [ J ]. Jiangxi Chinese medicine 2016 (02): 73-75).

[2] Wangshi Zhen, traditional Chinese medicine otorhinolaryngopharynx and larynx science (M version 2), Beijing, Chinese medicine Press 2011: 152-.

[3]Wu T,Yang X,Zeng X,et al.Traditional Chinese medicine in thetreatment of acute respiratory tract infections[J].Respiratory medicine,2008,102(8):1093-1098.

[4]Lu C,Song Y,Zhang J,et al.Yanshu spraying agent,a traditionalChinese medicine,relieves chronic pharyngitis in animals by anti-inflammatoryand antibacterial effects[J].Experimental and therapeutic medicine,2014,7(4):990-994.

[5] Chen nationality Qing, Zhu Hui, Chinese medicine tea substitute drink for treating chronic pharyngitis [ J ]. China and foreign health Abstract Magazine 2012(5):419 and 420.

[6] Clinic curative effect analysis of LIYAN SELF-LIYAN decoction for treating chronic pharyngitis [ J ] Chinese medicine clinic research, 2013,6(33):65-67.

[7] 45 cases of curative effect observation of a prescription for relieving cough by self-prepared mulberry cicada [ J ]. Yunnan Chinese medicine journal, 2014,35(11):38.

[8] Zhouqin, Liyanhua, chronic pharyngitis [ J ] research progress of external treatment of traditional Chinese medicine in Xinjiang 2015, (06):116 + 118.

[9] Observation of therapeutic effects of Shenyanmei and Xiayinge's Shuanghuanglian on chronic pharyngitis by ultrasonic aerosol inhalation [ J ]. J.Utility Med.J.2011, 7(22):443.

[10] Xufei, Chinese medicine aerosol inhalation for treating chronic pharyngitis [ J ]. inner Mongolia Chinese medicine, 2010,10:16-17.

[11]Lai K,Chen R,Lin J,et al.A prospective,multicenter survey oncauses of chronic cough in China[J].Chest,2013,143(3):613-620.

[12]Huang Y,Wu T,Zeng L,et al.Chinese medicinal herbs for sore throat[J].The Cochrane Library,2012.

[13] Zhao Yujuan, acupoint application therapy for treating chronic pharyngitis 160 cases [ J ] Chinese medicine guidance, 2012,18(9):71-73.

[14] He Miao, Liuyang, Li Ming Qing Aerosol for treating chronic pharyngitis 60 cases of clinical curative effect observation [ J ]. proceedings of Chengdu medical college, 2013,8(4):485 and 486.

[15]Wen Musheng.Prevention and Treatment for chronic pharyngitis byAcupoint Sticking Therapy:A Report of 100 Cases[J].Acupunci Tuina,Sci.2012,1(4):254-257.

[16] Xulijun tea bag is developed and expected in China [ J ] Chinese tea processing, 2007,5(3):15-16.

[17] The experimental study on the extraction of ganoderma lucidum tea bag polysaccharide by ultrasonic method [ J ] food and medicine 2006,8(01A):52-54.

[18] Liu Shutang, Jian Wen Mai, Dong Hai Rong, etc., Lei Xiang Zheng Qi bagged steeping drug technical test research is well-balanced [ J ]. Chinese herbal medicine, 1994,25(1):20-22.

[19] Chueagle, research on the optimization process of compound platycodon grandiflorum tea bag [ J ] Chinese medicine science and technology, 2006,13(1):38-39.

[20]C Murray R,K Chennupati S.Chronic streptococcal and non-streptococcal pharyngitis[J].Infectious Disorders-Drug Targets(FormerlyCurrent Drug Targets-Infectious Disorders),2012,12(4):281-285.

[21]Jiang H,She B,Liu W,et al.Efficacy and safety of Qi-Wei-Qing-Yanaerosol in treatment of acute pharyngitis(lung-stomach excess-heat syndrome):study protocol for a randomized controlled trial[J].Trials,2016,17(1):99.

[22]Sun Y,Zang Z,Xu X,et al.Experimental investigation of theimmunoregulatory and anti-inflammatory effects of the traditional Chinesemedicine“Li-Yan Zhi-Ke Granule”for relieving chronic pharyngitis in rats[J].Molecular biology reports,2011,38(1):199-203.

Although specific embodiments of the invention have been described in detail, those skilled in the art will appreciate. Various modifications and substitutions of those details may be made in light of the overall teachings of the disclosure, and such changes are intended to be within the scope of the present invention. The full scope of the invention is given by the appended claims and any equivalents thereof.

Claims (10)

1. A pharmaceutical composition comprising:

preferably, the first and second electrodes are formed of a metal,

the pharmaceutical composition comprises:

2. the pharmaceutical composition according to claim 1, in a unit dose of 2-10g, preferably 3-5g, more preferably 3 g.

3. The pharmaceutical composition according to any one of claims 1 to 2, which is a tea; preferably, it is packaged in the form of a teabag.

4. A pharmaceutical composition according to any one of claims 1 to 3, which is comminuted or non-comminuted; preferably pulverized; preferably, the pulverized medicinal powder passes through a No. 1 sieve; more preferably, the pulverized powder passes through a No. 1 sieve and cannot pass through a No. 5 sieve.

5. The pharmaceutical composition of any one of claims 1 to 4, having a water content of less than 12%; preferably, less than or equal to 10%; more preferably, less than or equal to 5%.

6. The pharmaceutical composition according to any one of claims 1 to 5, wherein, per 3g of the pharmaceutical composition:

the paeoniflorin is more than or equal to 5.78 mu g,

the content of liquiritin is more than or equal to 2.78 mug,

glycyrrhizic acid content is more than or equal to 4.30 mu g, and/or

The arctiin content is not less than 16.00 mu g;

preferably, the first and second electrodes are formed of a metal,

the paeoniflorin is more than or equal to 6 mu g,

the content of liquiritin is more than or equal to 2.8 mug,

glycyrrhizic acid content is more than or equal to 4.5 microgram, and/or

The arctiin content is more than or equal to 18 mu g;

more preferably still, the first and second liquid crystal compositions are,

the paeoniflorin is more than or equal to 7 mu g,

the content of liquiritin is more than or equal to 3 mug,

glycyrrhizic acid content is more than or equal to 5 microgram, and/or

The arctiin content is not less than 19 μ g.

7. An extract which is an aqueous or ethanolic extract of the pharmaceutical composition of any one of claims 1-6.

8. Use of the pharmaceutical composition of any one of claims 1-6 or the extract of claim 7 for the manufacture of a medicament selected from any one of (1) to (4) as follows:

(1) a medicine for tonifying qi, moistening lung, clearing throat, relieving sore throat and/or removing dirt and turbid pathogen;

(2) a medicament for the treatment and/or prevention of pharyngitis; preferably, the pharyngitis is chronic pharyngitis; preferably, the pharyngitis is pharyngitis caused by novel coronavirus pneumonia (Corona Virus Disease 2019, COVID-19);

(3) an expectorant, preferably a drug for expectoration in patients with novel coronavirus pneumonia (Corona Virus Disease 2019, COVID-19);

(4) the cough relieving medicine is preferably used for relieving cough of patients with novel coronavirus pneumonia (Corona Virus Disease 2019, COVID-19).

9. A process for preparing a pharmaceutical composition according to any one of claims 1 to 6, comprising the steps of:

(1) pulverizing the medicinal materials, and sieving with No. 1 sieve and No. 5 sieve to obtain coarse powder between No. 1 sieve and No. 5 sieve; preferably, the No. 1 oversize powder is crushed again and passes through the No. 1 sieve and the No. 5 sieve to obtain coarse powder between the No. 1 sieve and the No. 5 sieve, and the coarse powder is combined with the coarse powder obtained in the previous step;

(2) uniformly mixing the obtained coarse powder;

(3) packaging and sterilizing;

preferably, in the step (1), radix ophiopogonis and rhizoma cimicifugae are crushed together, and/or fructus arctii and radix paeoniae rubra are crushed together; preferably, the remaining medicinal materials are pulverized separately or together.

10. A method for quality control or quality detection of the pharmaceutical composition of any one of claims 1 to 6, comprising the step of detecting the content of paeoniflorin, liquiritin, glycyrrhizic acid and arctiin, wherein, calculated per 3g of the pharmaceutical composition,

if so:

the content of paeoniflorin is more than or equal to 5.78 mug,

the content of liquiritin is more than or equal to 2.78 mug,

glycyrrhizic acid content of not less than 4.30 μ g, and

the arctiin content is not less than 16.00 mug,

the quality of the pharmaceutical composition is qualified;

preferably, if:

the content of paeoniflorin is more than or equal to 6 mug,

the content of liquiritin is more than or equal to 2.8 mug,

glycyrrhizic acid content of not less than 4.5 μ g, and

the arctiin content is more than or equal to 18 mug,

the quality of the pharmaceutical composition is qualified;

more preferably, if:

the content of paeoniflorin is more than or equal to 7 mug,

the content of liquiritin is more than or equal to 3 mug,

glycyrrhizic acid content is more than or equal to 5 mug, and

the arctiin content is not less than 19 mug,

the quality of the pharmaceutical composition is qualified;

preferably, the contents of paeoniflorin, liquiritin, glycyrrhizic acid and arctiin are detected by high performance liquid chromatography;

preferably, the chromatographic conditions are as follows:

a chromatographic column: CosmosilC₁₈A chromatographic column;

mobile phase: acetonitrile (a) and 0.2% aqueous phosphoric acid (B);

flow rate: 1.0 mL/min^-1；

Wavelength: 232 nm;

sample introduction amount: 10 mu L of the solution;

column temperature: 30 ℃;

gradient elution procedure: 0-10 min, 10% -20% A; 10-18 min, 20% -25% A; 18-25 min, 25% -38% A; 25-30 min, 38% -43% A; 30-40 min, 43% -50% A; 40-43 min, 50-95% A.

Images